Overcoming immune evasion with innovative multi-target approaches for glioblastoma

Area of Science:

• Neuro-oncology
• Immunology
• Cancer Biology

Background:

• Glioblastoma (GBM) exhibits aggressive proliferation, invasion, and metastasis.
• Tumor immune evasion is a critical barrier to effective GBM therapy.
• Current monotherapies show limited clinical benefit due to GBM's adaptive immune evasion.

Purpose of the Study:

• To review glioblastoma's intricate immune evasion mechanisms.
• To explore the role of immune checkpoint inhibitors (ICIs) within the tumor microenvironment.
• To discuss recent clinical advancements and future therapeutic directions for GBM.

Main Methods:

• Literature review of glioblastoma immunology and therapy.
• Analysis of immune evasion strategies employed by GBM cells.
• Evaluation of clinical trial data for immunotherapy in GBM.

Main Results:

• GBM employs a multifactorial network to evade the immune system.
• ICIs show potential but face challenges within the GBM tumor microenvironment.
• Adaptive immune evasion necessitates novel therapeutic approaches.

Conclusions:

• Understanding GBM immune evasion is crucial for therapeutic development.
• Combination therapies may overcome resistance to monotherapies.
• Future research should focus on targeting GBM's immune evasion pathways.